(Reuters) - Dialysis centers in the United States are rolling out COVID-19 antibody treatments this week, a new path for delivery of Eli Lilly and Regeneron drugs approved for emergency use but facing skepticism and logistical problems in some hospitals.
Supplies of the drugs are piling up as hospitals grapple with overflowing wards and mass vaccinations. Kidney dialysis patients are among those most at risk from COVID-19, which is especially deadly among people with chronic illnesses.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!